Abstract: Indian biotechnology industry is increasing in its size on a global biotech industry map. It is counted among the top 12 global biotech hotspots and is the 3rd largest in terms of number of biotech companies in Asia Pacific region. The global biotech industry size is currently US$63.8 billion. The biotechnology industry has touched 2 billion dollar (Approximately 8000 crore) mark in revenue for 2006-07 from the 1 billion dollars (Approximately 4000 crore) in 2004-05. The Associated Chambers of Commerce and Industry in India (Assocham) has revealed that Indian biotechnology sector should grow to US$5 Billion by the year 2009-2010. Bio Pharma remained the largest contributor to the sector with a value contribution of Rs. 3,570 crore accounting for a 75% contribution. The biopharma sector touched 1.4 billion dollar mark while the bio-services sector reached 250 million dollars. The bio-agri sector crossed the 250 million dollar mark. Investments in the Indian biotechnology sector crossed 580 million dollars in 2006-2007 with Bangalore alone witnessing more than Rs 1000 crore outlay from companies like Jubilant, AstraZeneca, GE Healthcare and Biocon. The biotechnology companies R&D spend was on an average 3 per cent of sales. The industry grew by 30 per cent, with bio-agri scoring the highest growth rate at 50 per cent and largest acreage of 9 million. India is presently ranked number 3 (following Japan and Korea) in the Asia Pacific region in Biotechnology by Ernst &Young.
Major Players and Segments
Biotechnology Industry includes dedicated biotechnology firms, usually university spinoffs, researching disease mechanisms at the molecular level, companies serving both the pharmaceutical and biotechnology industries with platform technologies that can speed up the drug discovery process or improve drug delivery and Traditional pharmaceutical companies (“big pharma”) marketing drugs developed by biotechnology firms. According to Assocham, there are above 300 biotechnology firms in India that focus on various facets of the value-chain, however, nearly 50% of the revenue is concentrated with top ten players. In India, bio-generics and vaccines are the most common interest areas for major firms such as Bharat Biotech, Dr Reddy’s Lab, Workhardt, Zydus, etc. The country is already the 2nd largest maker of vaccines that are used by kids and these vaccines are exported to more than 100 countries. It is expected that Indian pharmaceutical firms will supply 90% of the worldwide demand for measles-vaccine in the years to come. Apart from vaccines, diagnostics is another rapidly growing segment of Indian bio pharma sector. In 2004, diagnostic market recorded sales of for US$ 138.2 Million.
|
The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email:
info@kppub.com /
fpc@vsnl.com, Website:
http://www.kppub.com |
